Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
The development of orally active pulmonary vasodilators has been a major breakthrough in the treatment of pulmonary arterial hypertension (PAH). Orally active medications greatly enhanced patient access to PAH treatment and increased an interest in the diagnosis and treatment of this disease that still continues. Four different orally active drugs are currently available for the treatment of PAH and several more are undergoing evaluation. This article discusses the mechanisms by which endothelin receptor antagonists and phosphodiesterase-5 inhibitors mitigate pulmonary hypertensive responses, and reviews the most recent data concerning their efficacy and limitations in the treatment of PAH.
['Channick|Richard|R|', 'Preston|Iona|I|', 'Klinger|James R|JR|']
D000284:Administration, Oral D002243:Carbolines D065128:Endothelin Receptor Antagonists D065627:Familial Primary Pulmonary Hypertension D006801:Humans D006976:Hypertension, Pulmonary D058986:Phosphodiesterase 5 Inhibitors D010879:Piperazines D011687:Purines D000068677:Sildenafil Citrate D013450:Sulfones D000068581:Tadalafil
Oral therapy Pulmonary arterial hypertension Endothelin receptor antagonists Phosphodiesterase-5 inhibitors